Skip to main content

Table 1 Effect ovarian cancer ascites on drug-induced cell death

From: The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

Ovarian cancer ascites Cisplatin
IC50 (ng/ml)
Paclitaxel
IC50 (ng/ml)
Doxorubicin
IC50 (ng/ml)
Etoposide
IC50 (ng/ml)
Vinorelbine
IC50 (ng/ml)
TRAIL
IC50 (ng/ml)
fluids - + - + - + - + - + - +
346 746 ± 38 1400 ± 24 16 ± 7 100 ± 9 86 ± 8 250 ± 15 2183 ± 147 7500 ± 245 4.1 ± 0.25 10 ± 1 8.4 ± 2.7 28.6 ± 4
432 746 ± 38 900 ± 43 16 ± 7 16 ± 3 86 ± 8 70 ± 10 2183 ± 147 2000 ± 87 4.1 ± 0.25 4.4 ± 0.4 8.4 ± 2.7 8.1 ± 2.8
488 746 ± 38 900 ± 23 16 ± 7 37 ± 5 86 ± 8 107 ± 13 2183 ± 147 6000 ± 184 4.1 ± 0.25 6.3 ± 1 8.4 ± 2.7 9.0 ± 3
508 746 ± 38 2300 ± 16 16 ± 7 16 ± 4 86 ± 8 145 ± 5 2183 ± 147 >50000 4.1 ± 0.25 >1000 8.4 ± 2.7 38 ± 4.2
509 746 ± 38 3000 ± 54 16 ± 7 80 ± 3 86 ± 8 750 ± 8 2183 ± 147 >50000 4.1 ± 0.25 >1000 8.4 ± 2.7 32 ± 3.1
551 746 ± 38 820 ± 47 16 ± 7 13 ± 4 86 ± 8 112 ± 12 2183 ± 147 4600 ± 231 4.1 ± 0.25 6.6 ± 0.2 8.4 ± 2.7 15 ± 5.4